Please login to the form below

Not currently logged in
Email:
Password:

Dicerna

This page shows the latest Dicerna news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Boehringer bolsters NASH pipeline with $870m Yuhan deal

later this year, as well as a drug candidates for the disease covered by its recently expanded $201m collaboration with Dicerna Pharma.

Latest news

  • Alexion targets RNAi with $637m Dicerna deal Alexion targets RNAi with $637m Dicerna deal

    Bolsters pipeline ahead of Soliris patent protection loss. Alexion has signed a deal with RNAi specialists Dicerna to discover therapies for complement-mediated diseases. ... The deal gives Dicerna $22m in upfront payments and it will also eligible to

  • Boehringer adds to pipeline again with €628m Autifony CNS deal Boehringer adds to pipeline again with €628m Autifony CNS deal

    This is the second licensing deal for Boehringer in the last few weeks, coming after it added a non-alcoholic steatohepatitis (NASH) candidate from Dicerna in a $201m deal.

  • Boehringer bolsters NASH pipeline with $201m Dicerna deal Boehringer bolsters NASH pipeline with $201m Dicerna deal

    specialist Dicerna. ... Dicerna is a US specialist in RNA interference (RNAi), a technique that switches off messenger RNA associated with specific genes and prevents them from generating their corresponding proteins.

  • 15 years since the first paper published on RNA interference 15 years since the first paper published on RNA interference

    Alnylam is also involved in collaborations with companies including Genzyme, the Medicines Company and Takeda, while other biotechs, such as Dicerna, RXi and Tekmira, all have their own programmes, demonstrating a

  • RNA interference rebirth RNA interference rebirth

    founder of RNAi company Dicerna. ... Most companies active in the RNAi field, such as Alnylam, Dicerna, RXi and big pharma players like Novartis and Merck, have elected to develop double-stranded, small interfering RNA (siRNA) oligonucleotides

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.

  • Deal Watch - May 2017 Deal Watch - May 2017

    Intas (pharma). 106. Bain and others. Investment. Dicerna (biotech). 70. M&A without debt.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Dr Stephen Hoffman joins Bicycle Therapeutics Dr Stephen Hoffman joins Bicycle Therapeutics

    He is also a member of the board of directors of AcelRx Pharmaceuticals, Dicerna Pharmaceuticals and Genocea Biosciences.

  • Dicerna appoints chief financial officer Dicerna appoints chief financial officer

    US biopharmaceutical firm Dicerna has appointed Jack Green as its chief financial officer. ... Since joining the company as interim CFO, Jack's strategic and business insights have added tremendous value and will be instrumental to the continued growth

  • Bruce Peacock joins Dicerna from Ophthotech Bruce Peacock joins Dicerna from Ophthotech

    US-based biopharma company Dicerna Pharmaceuticals has appointed Bruce Peacock to its board of directors and audit committee. ... Douglas Fambrough, CEO at Dicerna, said: “Bruce Peacock is a recognised leader in the biotech industry.

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics